I turn complex medical science into clear, honest answers, so you understand your body and make choices with confidence.
Dr. Amin Hedayat is triple board-certified in dermatopathology, anatomic pathology, and clinical pathology. He serves as a Medical School Assistant Clinical Professor and practices medicine full time.
He completed his dermatopathology fellowship at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, where he was mentored by internationally renowned dermatopathologists and dermatologists. He completed his residency at Dartmouth.
Dr. Hedayat has authored numerous peer-reviewed publications and book chapters on advanced molecular testing in melanoma, melanocytic tumors, and cutaneous lymphoma. He has presented at national and international scientific meetings, and he is passionate about combating skin cancer through clinical practice, education, and research.
He completed his obesity medicine education in line with the requirements of the American Board of Obesity Medicine.
His clinical focus is metabolic health and longevity: how insulin resistance and chronic inflammation shape how long, and how well, people live. He has also trained in facial aesthetics.
Take what the evidence shows, cut the hype, and put it in plain language.
New lectures, podcast episodes, and research updates, wherever you prefer to learn.
What semaglutide, tirzepatide, and the newer peptides actually do, what the trials show, and where the longevity evidence stands.
Obesity is a disease, not a willpower problem. Hormones, genetics, and metabolism set body weight, and they fight hard to defend it. I treat it like any chronic condition: medication when the evidence supports it, nutrition that fits real life, and follow-up that lasts.
A biopsy lands on my desk, and the tissue tells a story. My job is to read it. Under the microscope, I look at skin one cell at a time and name what is wrong. I catch melanoma hiding among ordinary moles, along with basal and squamous cell carcinoma. I sort out lymphomas that start in the skin, the rashes of lupus and psoriasis, infections, and blistering diseases. One slide can separate a harmless mole from a melanoma that needs treatment now.
Chairman of the board of the American Melanoma Institute, with published work on molecular testing in melanoma and cutaneous lymphoma.
I break down the GLP-1 medications, the emerging therapies, and the metabolic science underneath them.